Arbutus Biopharma: 10% owner Roivant Sciences sold 8,967,383 shares

What happened

• Roivant Sciences Ltd., reported as a 10% owner, disposed of 8,967,383 shares to the issuer on Oct 1, 2026 at $5.00 per share, for $44,836,915. The Form 4 was filed on Oct 5, 2026.

Key details

• Transaction date and price: Oct 1, 2026; disposition to the issuer (transaction code D) at $5.00 per share.
• Shares owned after the transaction: not stated in the filing.
• Reporting person note from the filing: Roivant Sciences may be deemed a "director by deputization" under Section 16 because Matthew Gline and Joseph Bishop serve on the issuer's board on behalf of Roivant and are employees of Roivant Sciences, Inc. Lindsay Androski also serves on the issuer's board and is an employee of Roivant Sciences, Inc. and separately serves as president and chief executive officer of the issuer.
• Filing and report dates: period of report Oct 1, 2026; Form 4 filed Oct 5, 2026. Accession number 0001140361-26-038692.

Why it may matter

• Roivant Sciences is reported as a 10% owner, i.e., a large holder rather than an individual executive.
• The transaction is reported as a disposition to the issuer (shares sold back to the company), not an open-market sale.
• A filing does not show why the insider traded or why the company acted.